All In Biotech

Investigational drug · Phase 2

QLC5513

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Solid Tumors.

Phase 2

Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "QLC5513"

First trial start

2025

Dec 30, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "QLC5513", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Metastatic Solid Tumors

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "QLC5513" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Metastatic Solid Tumors

  • R-DXdDS 6000a, MK-5909Phase 310 trials

    Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

  • EzabenlimabBI 754091Phase 32 trials

    Boehringer Ingelheim · Advanced Cancer, Neoplasm Metastasis, Advanced Tumors

  • RMC-6291ElironrasibPhase 23 trials

    Revolution Medicines, Inc. · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer

  • AVZO-103Phase 21 trial

    Avenzo Therapeutics, Inc. · Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors

  • AVZO-1418Phase 21 trial

    Avenzo Therapeutics, Inc. · Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors

  • BI 754111Phase 21 trial

    Boehringer Ingelheim · Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors

  • BI 836880Phase 21 trial

    Boehringer Ingelheim · Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors

  • BPR-6023021Phase 21 trial

    Chengdu Syncor Pharmaceutical Co., Ltd. · Metastatic Solid Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.